The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
Open accessAbstract
About 246 million people worldwide had diabetes in 2007. The global figure of people with diabetes is projected to increase to 370 million in 2030. As the prevalence of diabetes has risen to epidemic proportions worldwide, diabetic nephropathy has become one of the most challenging health problems. Therapeutic options such as strict blood glucose and blood pressure controls are effective for preventing diabetic nephropathy, but are far from satisfactory, and the number of diabetic patients on end‐stage renal disease is still increasing. Therefore, a novel therapeutic strategy that could halt the progression of diabetic nephropathy should be developed. There is accumulating evidence that advanced glycation end products (AGEs), senescent macroprotein derivatives formed at an accelerated rate under diabetes, play a role in diabetic nephropathy via oxidative stress generation. In this paper, we review the pathophysiological role of AGEs and their receptor (RAGE)‐oxidative stress system in diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
Flier, J. S., Underhill, L. H., Brownlee, M., Cerami, A., & Vlassara, H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805193182007 · Cited by 2,511
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441
Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Rathmann, W., & Giani, G. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2568 · Cited by 1,994
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J., Chow, W. S., Stern, D., & Schmidt, A. M. (1998) · Nature Medicine · doi:10.1038/2012 · Cited by 1,104
Advanced Glycosylation End Products in Patients with Diabetic Nephropathy
Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Delaney, V., Friedman, E. A., Cerami, A., & Vlassara, H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109193251202 · Cited by 918
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E., & Border, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1814 · Cited by 830
Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-κB
Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P. M., Chen, J., Hong, M., Luther, T., Henle, T., Klöting, I., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2792 · Cited by 824
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Diabetes mellitus : a fundamental and clinical text
LeRoith, D., Taylor, S. I., & Olefsky, J. M. (2004) · Cited by 699
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Glycation and Diabetic Complications
Brownlee, M. (1994) · Diabetes · doi:10.2337/diab.43.6.836 · Cited by 632
Wendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63909-0 · Cited by 600
Nephropathy in Patients with Type 2 Diabetes
Remuzzi, G., Schieppati, A., & Ruggenenti, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011773 · Cited by 587
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
Dyer, D. G., Blackledge, J. A., Thorpe, S. R., & Baynes, J. W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99007-1 · Cited by 535
Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging
Bucala, R., & Cerami, A. (1992) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60961-8 · Cited by 526
TANJI, N., MARKOWITZ, G. S., FU, C., KISLINGER, T., TAGUCHI, A., PISCHETSRIEDER, M., STERN, D., SCHMIDT, A. M., & D'AGATI, V. D. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1191656 · Cited by 487
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S.-I., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11771 · Cited by 475
Self-citationOldfield, M. D., Bach, L. A., Forbes, J. M., Nikolic-Paterson, D., McRobert, A., Thallas, V., Atkins, R. C., Osicka, T., Jerums, G., & Cooper, M. E. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11951 · Cited by 472
Monnier, V. M., Bautista, O., Kenny, D., Sell, D. R., Fogarty, J., Dahms, W., Cleary, P. A., Lachin, J., & Genuth, S. (1999) · Diabetes · doi:10.2337/diabetes.48.4.870 · Cited by 469
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Grandhee, S. K., & Monnier, V. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99006-x · Cited by 459
Yamagishi, S.-I., & Imaizumi, T. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054367300 · Cited by 452
Self-citationSoulis-Liparota, T., Cooper, M., Papazoglou, D., Clarke, B., & Jerums, G. (1991) · Diabetes · doi:10.2337/diab.40.10.1328 · Cited by 447
DE VRIESE, A. S., TILTON, R. G., ELGER, M., STEPHAN, C. C., KRIZ, W., & LAMEIRE, N. H. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v125993 · Cited by 442
The glomerular mesangial cell: an expanding role for a specialized pericyte
Schlondorff, D. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.4.3308611 · Cited by 430
Genuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Tanaka, N., Yonekura, H., Yamagishi, S.-I., Fujimori, H., Yamamoto, Y., & Yamamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001235200 · Cited by 424
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
Lopez, A., & Marantz, P. R. (1994) · PubMed · Cited by 424
RISER, B. L., DENICHILO, M., CORTES, P., BAKER, C., GRONDIN, J. M., YEE, J., & NARINS, R. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11125 · Cited by 388
Advanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
PEDF: a multifaceted neurotrophic factor
Tombran-Tink, J., & Barnstable, C. J. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1176 · Cited by 367
Thallas-Bonke, V., Thorpe, S. R., Coughlan, M. T., Fukami, K., Yap, F. Y. T., Sourris, K. C., Penfold, S. A., Bach, L. A., Cooper, M. E., & Forbes, J. M. (2008) · Diabetes · doi:10.2337/db07-1119 · Cited by 345
Novel inhibitors of advanced glycation endproducts
Rahbar, S., & Figarola, J. L. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.009 · Cited by 329
THORPE SR ROLE OF OXIDATIVE STRESS IN DIABETIC COMPLICATIONS: A NEW PERSPECTIVE ON AN OLD PARADIGM
Baynes, J. (1999) · Cited by 326
Yamagishi, S.-I., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M., & Makita, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202634200 · Cited by 310
Self-citationAdvanced glycation end products up-regulate gene expression found in diabetic glomerular disease.
Yang, C. W., Vlassara, H., Peten, E. P., He, C. J., Striker, G. E., & Striker, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9436 · Cited by 294
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032418.67267.f2 · Cited by 290
Glycation Induces Formation of Amyloid Cross-β Structure in Albumin
Bouma, B., Kroon-Batenburg, L. M. J., Wu, Y.-P., Brünjes, B., Posthuma, G., Kranenburg, O., de Groot, P. G., Voest, E. E., & Gebbink, M. F. B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303925200 · Cited by 286
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Role of angiotensin II in diabetic nephropathy
Leehey, D. J., Singh, A. K., Alavi, N., & Singh, R. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07715.x · Cited by 274
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
Banba, N., Nakamura, T., Matsumura, M., Kuroda, H., Hattori, Y., & Kasai, K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00214.x · Cited by 267
Forbes, J. M., Thallas, V., Thomas, M. C., Founds, H. W., Burns, W. C., Jerums, G., & Cooper, M. E. (2003) · The FASEB Journal · doi:10.1096/fj.02-1102fje · Cited by 263
SUZUKI, D., MIYATA, T., SAOTOME, N., HORIE, K., INAGI, R., YASUDA, Y., UCHIDA, K., IZUHARA, Y., YAGAME, M., SAKAI, H., et al. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v104822 · Cited by 254
Beisswenger, P. J., Makita, Z., Curphey, T. J., Moore, L. L., Jean, S., Brinck-Johnsen, T., Bucala, R., & Vlassara, H. (1995) · Diabetes · doi:10.2337/diab.44.7.824 · Cited by 253
Role of reactive oxygen species in the pathogenesis of diabetic nephropathy
Ha, H., Hwang, I.-A., Park, J. H., & Lee, H. B. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.017 · Cited by 249
Burns, W. C., Twigg, S. M., Forbes, J. M., Pete, J., Tikellis, C., Thallas-Bonke, V., Thomas, M. C., Cooper, M. E., & Kantharidis, P. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050525 · Cited by 243
Renal catabolism of advanced glycation end products: the fate of pentosidine
Miyata, T., Ueda, Y., Horie, K., Nangaku, M., Tanaka, S., de Strihou, C. V. Y., & Kurokawa, K. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00756.x · Cited by 227
AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interaction
Fukami, K., Ueda, S., Yamagishi, S.-I., Kato, S., Inagaki, Y., Takeuchi, M., Motomiya, Y., Bucala, R., Iida, S., Tamaki, K., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66004.x · Cited by 218
Self-citationYamagishi, S.-I., Nakamura, K., Matsui, T., Inagaki, Y., Takenaka, K., Jinnouchi, Y., Yoshida, Y., Matsuura, T., Narama, I., Motomiya, Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602110200 · Cited by 217
Self-citationTsuchida, K., Makita, Z., Yamagishi, S., Atsumi, T., Miyoshi, H., Obara, S., Ishida, M., Ishikawa, S., Yasumura, K., & Koike, T. (1999) · Diabetologia · doi:10.1007/s001250051198 · Cited by 215
Self-citationYamagishi, S.-I., Amano, S., Inagaki, Y., Okamoto, T., Koga, K., Sasaki, N., Yamamoto, H., Takeuchi, M., & Makita, Z. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6312 · Cited by 209
Self-citationRole of angiotensin II in glucose-induced inhibition of mesangial matrix degradation.
Singh, R., Alavi, N., Singh, A. K., & Leehey, D. J. (1999) · Diabetes · doi:10.2337/diabetes.48.10.2066 · Cited by 197
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Wendt, T., Bucciarelli, L., Qu, W., Lu, Y., Yan, S. F., Stern, D. M., & Schmidt, A. M. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0024-4 · Cited by 176
Hormonal modulation of glomerular function
Dworkin, L. D., Ichikawa, I., & Brenner, B. M. (1983) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1983.244.2.f95 · Cited by 173
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility
Mott, J. D., Khalifah, R. G., Nagase, H., Shield, C. F., Hudson, J. K., & Hudson, B. G. (1997) · Kidney International · doi:10.1038/ki.1997.455 · Cited by 170
Atherosclerosis and diabetes: The rage connection
Schmidt, A. M., & Stern, D. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0082-4 · Cited by 167
Miura, J., Yamagishi, S., Uchigata, Y., Takeuchi, M., Yamamoto, H., Makita, Z., & Iwamoto, Y. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00183-6 · Cited by 157
Self-citationYamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., & Takeuchi, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00752.x · Cited by 152
Self-citationMolecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Yamagishi, S., Fukami, K., Ueda, S., & Okuda, S. (2007) · Current Drug Targets · doi:10.2174/138945007781386884 · Cited by 151
Self-citationTwigg, S. M., Cao, Z., McLennan, S., Burns, W. C., Brammar, G. C., Forbes, J. M., & Cooper, M. E. (2002) · Endocrinology · doi:10.1210/en.2002-220619 · Cited by 143
Yamagishi, S., Nakamura, K., Matsui, T., Ueda, S., Fukami, K., & Okuda, S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.983 · Cited by 141
Self-citationThiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products
Marx, N., Walcher, D., Ivanova, N., Rautzenberg, K., Jung, A., Friedl, R., Hombach, V., Caterina, R. D., Basta, G., Wautier, M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.10.2662 · Cited by 136
Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney
Thomas, M. C., Tikellis, C., Burns, W. M., Bialkowski, K., Cao, Z., Coughlan, M. T., Jandeleit-Dahm, K. A. M., Cooper, M. E., & Forbes, J. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010013 · Cited by 136
Yamagishi, S., Ueda, S., & Okuda, S. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781757051 · Cited by 119
Self-citationZhang, S., Filep, J. G., Hohman, T. C., Tang, S., Ingelfinger, J. R., & Chan, J. S. D. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00271.x · Cited by 118
Yoshida, T., Yamagishi, S., Nakamura, K., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0437-7 · Cited by 108
Self-citationConnective Tissue Growth Factor Is Increased in Plasma of Type 1 Diabetic Patients With Nephropathy
Roestenberg, P., van Nieuwenhoven, F. A., Wieten, L., de Boer, P., Diekman, T., Tiller, A. M., Wiersinga, W. M., Oliver, N., Usinger, W. R., Weitz, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1164 · Cited by 108
Chang, P.-C., Chen, T.-H., Chang, C.-J., Hou, C.-C., Chan, P., & Lee, H.-M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00602.x · Cited by 101
SILBIGER, S. R., Crowley, S. T., Shan, Z., Brownlee, M., Satriano, J. A., & Schlöndorff, D. (1993) · Kidney International · doi:10.1038/ki.1993.120 · Cited by 99
Tanimoto, M., Gohda, T., Kaneko, S., Hagiwara, S., Murakoshi, M., Aoki, T., Yamada, K. H., Ito, T., Matsumoto, M., Horikoshi, S., et al. (2007) · Metabolism · doi:10.1016/j.metabol.2006.08.026 · Cited by 94
Wang, K., Zhou, Z., Zhang, M., Fan, L., Forudi, F., Zhou, X., Qu, W., Lincoff, A. M., Schmidt, A. M., Topol, E. J., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095125 · Cited by 91
Salutary Effect of Pigment Epithelium–Derived Factor in Diabetic Nephropathy
Wang, J. J., Zhang, S. X., Mott, R., Knapp, R. R., Cao, W., Lau, K., & Ma, J. (2006) · Diabetes · doi:10.2337/db05-1448 · Cited by 87
Wang, J. J., Zhang, S. X., Lu, K., Chen, Y., Mott, R., Sato, S., & Ma, J. (2005) · Diabetes · doi:10.2337/diabetes.54.1.243 · Cited by 86
Galler, A., Müller, G., Schinzel, R., Kratzsch, J., Kieß, W., & Münch, G. W. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2609 · Cited by 82
Yamagishi, S., Nakamura, K., & Matsui, T. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.006 · Cited by 81
Self-citationSerum levels of low molecular weight advanced glycation end products in diabetic subjects
Sharp, P. S., Rainbow, S. J., & Mukherjee, S. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00973.x · Cited by 79
Tang, S. C. W., Leung, J. C. K., Chan, L. Y. Y., Tsang, A. W. L., & Lai, K. N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005101113 · Cited by 79
Yamagishi, S., Matsui, T., Nakamura, K., Takeuchi, M., & Imaizumi, T. (2006) · Microvascular Research · doi:10.1016/j.mvr.2006.04.002 · Cited by 75
Self-citationRenal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice
Jensen, L. J. N., Denner, L. A., Schrijvers, B. F., Tilton, R. G., Rasch, R., & Flyvbjerg, A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06524 · Cited by 75
Yamagishi, S., Matsui, T., & Nakamura, K. (2007) · Current Drug Targets · doi:10.2174/138945007782151298 · Cited by 73
Self-citationLow-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes
Thomas, M. C., Tsalamandris, C., MacIsaac, R. J., Medley, T. L., Kingwell, B. A., Cooper, M. E., Jerums, G., & Alberti, D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00868.x · Cited by 72
Steffes, M. W., Molitch, M. E., Chavers, B. M., Cleary, P. A., & Lachin, J. M. (2003) · JAMA · Cited by 65
Davis, B. J., Forbes, J. M., Thomas, M. C., Jerums, G., Burns, W. C., Kawachi, H., Allen, T. J., & Cooper, M. E. (2004) · Diabetologia · doi:10.1007/s00125-003-1256-8 · Cited by 63
Yamagishi, S., Nakamura, K., & Matsui, T. (2007) · Current Molecular Medicine · doi:10.2174/156652407781387073 · Cited by 62
Self-citationŠebeková, K., Gazdíková, K., Syrova, D., et al. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001541 · Cited by 60
Diabetes and Advanced Glycation End Products
Vlassara, H. (2001) · Humana Press eBooks · doi:10.1385/1-59259-091-8:81 · Cited by 54
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111771 · Cited by 54
Self-citationSuzuki, D., Toyoda, M., Yamamoto, N., Miyauchi, M., Katoh, M., Kimura, M., Maruyama, M., Honma, M., Umezono, T., & Yagame, M. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1557 · Cited by 50
Yamagishi, S., Amano, S., Inagaki, Y., Okamoto, T., Takeuchi, M., & Makita, Z. (2002) · Molecular Medicine · doi:10.1007/bf03402164 · Cited by 45
Self-citationYamagishi, S., Matsui, T., Nakamura, K., Takeuchi, M., & Inoue, H. (2008) · Protein and Peptide Letters · doi:10.2174/092986608785203746 · Cited by 44
Self-citationSaisho, Y., Komiya, N., & Hirose, H. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.04.015 · Cited by 44
Ma, L., Gao, H., Li, B., Ma, Y., You, B.-A., & Zhang, F.-L. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31803c5616 · Cited by 42
Yamagishi, S., Matsui, T., Nakamura, K., Ueda, S., Noda, Y., & Imaizumi, T. (2008) · Current Drug Targets · doi:10.2174/138945008786786154 · Cited by 40
Self-citationYe, S. D., Zheng, M., Zhao, L., Qian, Y., Yao, X., Ren, A., Li, S. M., & Jing, C. Y. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02203.x · Cited by 30
Yoshida, T., Yamagishi, S., Matsui, T., Nakamura, K., Ueno, T., Takeuchi, M., & Sata, M. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600204 · Cited by 25
Self-citationNovel Therapeutic Targets for Diabetic Nephropathy
Fukami, K., Yamagishi, S., Ueda, S., & Okuda, S. (2007) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153007780832118 · Cited by 23
Self-citationDeuther‐Conrad, W., Franke, S., Sommer, M., Henle, T., & Stein, G. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.59780063.x · Cited by 21
Advanced Glycation End Products and the Pathogenesis of Diabetic Nephropathy
Yamagishi, S., Takeuchi, M., & Makita, Z. (2001) · KARGER eBooks · doi:10.1159/000060150 · Cited by 12
Self-citationDeuther‐Conrad, W., Franke, S., Sommer, M., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.07815.x · Cited by 10
Cited by
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
Bouayed, J., & Bohn, T. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.4.12858 · Cited by 1,095
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
Domingueti, C. P., Dusse, L. M. S., Carvalho, M. D. G., de Sousa, L. P., Gomes, K. B., & Fernandes, A. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.018 · Cited by 647
Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.-B., Park, Y. M., Salekdeh, G. H., & Lee, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.030 · Cited by 357
Metadata
- Authors
- Yamagishi, S.-I., & Matsui, T.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 3
- Issue
- 2
- Pages
- 101-108
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2060075831
- Cited by
- 397
- References
- 122
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.